Overview

  • Product name
    Anti-non-muscle Myosin IIA antibody [EPR8965]
    See all non-muscle Myosin IIA primary antibodies
  • Description
    Rabbit monoclonal [EPR8965] to non-muscle Myosin IIA
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IF, Flow Cytmore details
    Unsuitable for: IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human non-muscle Myosin IIA aa 1900-2000. The exact sequence is proprietary.

  • Positive control
    • HeLa, HT-29, Jurkat, HUVEC, Human fetal kidney, and A431 lysates, Human kidney and Human lung tissues, A431 and HeLa cells
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: 0.01% Sodium azide
    Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
  • Purity
    Tissue culture supernatant
  • Clonality
    Monoclonal
  • Clone number
    EPR8965
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab138498 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 230 kDa (predicted molecular weight: 227 kDa).
IHC-P 1/250 - 1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC/IF 1/250 - 1/500.
Flow Cyt 1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

 

  • Application notes
    Is unsuitable for IP.
  • Target

    • Function
      Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
    • Tissue specificity
      In the kidney, expressed in the glomeruli. Also expressed in leukocytes.
    • Involvement in disease
      Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
      Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
      Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
      Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
      Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
      Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
      Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
      Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
      Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
    • Sequence similarities
      Contains 1 IQ domain.
      Contains 1 myosin head-like domain.
    • Domain
      The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
    • Post-translational
      modifications
      ISGylated.
    • Information by UniProt
    • Database links
    • Alternative names
      • BDPLT 6 antibody
      • BDPLT6 antibody
      • Cellular myosin heavy chain antibody
      • Cellular myosin heavy chain type A antibody
      • DFNA 17 antibody
      • DFNA17 antibody
      • EPSTS antibody
      • FTNS antibody
      • MGC104539 antibody
      • MHA antibody
      • MYH 2A antibody
      • MYH 9 antibody
      • MYH2A antibody
      • MYH9 antibody
      • MYH9_HUMAN antibody
      • MYHas8 antibody
      • MyHC 2A antibody
      • MyHC IIa antibody
      • MyHC2A antibody
      • MyHCIIa antibody
      • MYHSA 2 antibody
      • MYHSA2 antibody
      • Myosin 9 antibody
      • Myosin heavy chain 9 antibody
      • Myosin heavy chain 9 non muscle antibody
      • Myosin heavy chain antibody
      • Myosin heavy chain non muscle IIa antibody
      • Myosin heavy chain nonmuscle IIa antibody
      • Myosin heavy polypeptide 2 antibody
      • Myosin heavy polypeptide 9 non muscle antibody
      • Myosin-9 antibody
      • Myosin9 antibody
      • NMHC II A antibody
      • NMMHC A antibody
      • NMMHC II a antibody
      • NMMHC II-a antibody
      • NMMHC IIA antibody
      • NMMHC-A antibody
      • NMMHC-IIA antibody
      • NMMHCA antibody
      • Non muscle myosin heavy chain A antibody
      • Non muscle myosin heavy chain antibody
      • Non muscle myosin heavy chain II A antibody
      • Non muscle myosin heavy polypeptide 9 antibody
      • non-muscle IIa antibody
      • Non-muscle myosin heavy chain A antibody
      • Non-muscle myosin heavy chain IIa antibody
      • Nonmuscle myosin heavy chain A antibody
      • Nonmuscle myosin heavy chain II A antibody
      • type A antibody
      see all

    Images

    • Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: non-muscle Myosin IIA knockout HAP1 cell lysate (20 µg)
      Lane 3: HeLa cell lysate (20 µg)
      Lane 4: HEK293 cell lysate (20 µg)
      Lanes 1 - 4: Merged signal (red and green). Green - ab138498 observed at 230 kDa. Red - loading control, ab18058, observed at 124 kDa.

      ab138498 was shown to specifically react with non-muscle Myosin IIA in wild-type HAP1 cells. No band was observed when non-muscle Myosin IIA knockout samples were examined. Wild-type and non-muscle Myosin IIA knockout samples were subjected to SDS-PAGE. ab138498 at a dilution of 1/1000 and ab18058 (loading control to Vinculin) at a dilution of 1/10,000 were incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

    • All lanes : Anti-non-muscle Myosin IIA antibody [EPR8965] (ab138498) at 1/1000 dilution

      Lane 1 : HeLa lysate
      Lane 2 : HT-29 lysate
      Lane 3 : Jurkat lysate
      Lane 4 : HUVEC lysate
      Lane 5 : Human fetal kidney lysate
      Lane 6 : A431 lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 227 kDa
      Observed band size: 230 kDa
      why is the actual band size different from the predicted?

    • Immunohistochemical analysis of paraffin embedded Human kidney tissue labelling non-muscle Myosin IIA with ab138498 antibody at a dilution of 1/250.
    • Immunohistochemical analysis of paraffin embedded Human lung tissue labelling non-muscle Myosin IIA with ab138498 antibody at a dilution of 1/250.
    • Immunofluorescent analysis of A431 cells labelling non-muscle Myosin IIA with ab138498 at 1/250 dilution.
    • Immunofluorescent analysis of HeLa cells labelling non-muscle Myosin IIA with ab138498 at 1/250 dilution.

    References

    This product has been referenced in:
    See 1 Publication for this product

    Customer reviews and Q&As

    Application
    Western blot
    Loading amount
    15 µg
    Gel Running Conditions
    Reduced Denaturing (4-12%)
    Sample
    Human Cell lysate - other (293T)
    Specification
    293T
    Blocking step
    Milk as blocking agent for 30 minute(s) · Concentration: 10% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Aug 15 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up